PFIZER (PFE) Q2 2025 Profit Report

Pfizer On Tuesday he uploaded his guide for adjusted profits all year on cost cuts and his solid commercial performance this year.

The company also reported results of the second quarter that exceeded Wall Street estimates for the period, as the income of its Covid products and some other medications increased.

Pfizer's shares rose more than 4% on Tuesday.

Pfizer now expects the tight profits of the whole year to be between $ 2.90 and $ 3.10, compared to the previous guide of $ 2.80 to $ 3 per share. The company maintained its revenue forecast from 2025 from $ 61 billion to $ 64 billion.

“We collected our Adjusted Diluted EPS guide from 2025 per year throughout the year, demonstrating confidence in our ability to execute against our strategic priorities and deliver solid results for shareholders,” said Pfizer's financial director David Denton in a statement.

The entire year's perspective includes a single charge of $ 1.35 billion, or 20 cents per share, related to the company's license agreement with 3SBIO, a Chinese medication manufacturer, to develop and sell its treatment against cancer outside China. That position will be recorded in the third quarter, Pfizer said.

Without this position of agreement, Pfizer would have increased his perspective of adjusted profits by 30 cents, Denton said during a profit call with analysts on Tuesday.

The results also occur when Pfizer and other drug manufacturers fight with the calls of President Donald Trump at the lowest drug prices in the United States and prepare for their planned tariffs on the pharmaceutical products imported to the country.

Pfizer's prospects represent Trump's currently imposed tariffs on China, Canada and Mexico, as well as possible changes in medication prices this year based on a letter from the president last week that asks Pfizer to take measures to reduce medicines prices by September 29. The letter came after Trump signed an executive order that revived a controversial plan, the most favored policy of the nation “, which points to drug costs due to drug costs for prices prices for prices prices for prices prices for prices prices for prices prices for prices media. Abroad.

In Tuesday's call, the Pfizer CEO, Albert Bourla, refused to provide more details about the impact of the policy, in addition to confirming that the company has received the letter and is dedicated to “extremely productive” conversations with the Trump administration about the search for ways to reduce the prices of US drugs.

He said that the company and administration are looking for solutions that have the objective of “making medications affordable in the US. And, on the other hand, they make our industry more competitive compared to China, which progresses very quickly for us.”

In an interview with CNBC on Tuesday, Denton did not reveal specific costs for the impact of the most favored National Plan.

But Denton said the expected costs for the tariffs existing in the Pfizer guide are now less than $ 100 million. That is due to mitigation efforts, such as the inventory of repositioning in certain places and the anticipated ordering of some medications, he said.

In April, Pfizer executives said that the company's 2025 guide at that time included $ 150 million in expected costs of Trump's existing rates, but not the specific levies of the sector.

When asked about Trump's threat to impose up to 250% tariffs on pharmaceutical products, Denton said the company is analyzing all potential ranges by modeling the impact of tariffs.

But he added that “I think the devil will be in detail.”

This is what the company reported for the second quarter compared to what Wall Street expected, based on an LSEG analysts survey:

• Profit per action: 78 tight cents compared to 58 expected cents
• Revenue: $ 14.65 billion compared to $ 13.56 billion expected

For the second quarter, Pfizer reserved a net income of $ 2.91 billion, or 51 cents per share. That is compared to the net income of $ 41 million, or 1 penny per share, during the same period a year ago.

Excluding certain articles, including restructuring charges and costs associated with intangible assets, the company recorded profits per action of 78 cents for the quarter.

Pfizer reported revenues of $ 14.65 billion for the second quarter, 10% more than the same period of the previous year.

The results occur after Pfizer in April extended its cost reduction efforts, whose objective is to help the pharmaceutical giant to recover from the rapid decrease in its Covid business and the price of shares in recent years. With the additional movements announced in April, Pfizer now hopes to deliver around $ 7.7 billion in savings for the end of 2027 of two separate cost reduction programs.

The company said that the increase in sales was mainly driven by higher income for various products, including Pfizer Vyndaqel medications, which are used to treat a certain type of myocardiopathy, a heart muscle disease.

It also includes Pfizer Covid products. The company's COVID vaccine, Lation, booked $ 381 million in revenues for the second quarter. That increased 96% since the most annual period due to the highest Pfizer market share in the Covid Shot market and more contractual deliveries in certain international markets.

Analysts expected the shot to raise $ 205.3 million in sales for the quarter, according to Streetacount estimates.

The antiviral pill of Pfizer Paxlovid registered $ 427 million in sales for the second quarter. That increased 70% since the same period a year ago, mainly due to a higher net price of the United States for the pill, among other factors. This sales increase was compensated by lower COVID infections in the United States and certain global markets, and the lowest international purchases of the Paxlovid government.

Analysts expected the shot to raise $ 259.1 million in sales for the period, said Streetacount estimates.

The Pfizer, Padcev and Flowner bladder cancer medication, which shares with Bristol Myers Squibb, also contributed to income growth. Both analysts exceeded estimates for the period.

The company's income growth was compensated by the lowest sales of its Ibrance breast cancer drug. The medicine had a lower net price in the United States largely due to the impact of the discounts of higher manufacturers of the provisions of the Inflation Reduction Law that redesign the benefits of Medicare Part D, as well as the generic competition and the moment of shipments in certain international markets.